Patients Clinical trials fail in recruitment Clinical trials struggle in many areas, and significantly in recruitment.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital From static documents to strategic capability: The case for ... Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.
Digital Fail fast is not a cultural problem. It is a capital allocat... Even modest improvements in early predictive resolution can materially shift portfolio economics.
R&D Making AI work where it matters, with Rob DiCicco Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.
R&D Agentic AI and the human element: Building trustworthy autom... The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.